As of June 20, 2025, Aveo Pharmaceuticals Inc (AVEO) reports a ROA (Return on Assets) of -50.64%.
ROA (Return on Assets) evaluates how effectively a company turns its assets into profits, showcasing resource utilization.
Historical Trend of Aveo Pharmaceuticals Inc's ROA (Return on Assets)
Over recent years, Aveo Pharmaceuticals Inc's ROA (Return on Assets) has shown a stable trend. The table below summarizes the historical values:
| Date | ROA (Return on Assets) |
|---|---|
| 2021-12-31 | -50.64% |
| 2020-12-31 | -53.21% |
| 2019-12-31 | 18.58% |
| 2018-12-31 | -19.00% |
| 2017-12-31 | -129.48% |
This slight downward trend highlights how Aveo Pharmaceuticals Inc manages its efficiency in using assets to generate earnings over time.
Comparing Aveo Pharmaceuticals Inc's ROA (Return on Assets) to Peers
To better understand Aveo Pharmaceuticals Inc's position, it's useful to compare its ROA (Return on Assets) against industry peers. Below are selected comparisons:
| Company | ROA (Return on Assets) |
|---|---|
| Aveo Pharmaceuticals Inc (AVEO) | -50.64% |
| Regeneron Pharmaceuticals Inc (REGN) | 11.69% |
| Amgen Inc (AMGN) | 4.45% |
| Abbvie Inc (ABBV) | 3.17% |
| Gilead Sciences Inc (GILD) | 0.81% |
| Vertex Pharmaceuticals Inc (VRTX) | -2.38% |
Compared to its competitors, Aveo Pharmaceuticals Inc's ROA (Return on Assets) is about average compared to peers, indicating typical asset efficiency for the industry.